Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fate of Biogen's Plegridy in US/EU regulators’ hands

This article was originally published in Scrip

Executive Summary

Biogen Idec's biologic license application (BLA) for its pegylated subcutaneous injectable interferon, known as Plegridy (peginterferon beta-1a), will get a standard review at the US FDA, the firm revealed on 19 July, adding that the marketing authorization application (MAA) also has been validated by the European Medicines Agency, with the company seeking approval from both regulators for the drug as a treatment for relapsing forms of multiple sclerosis (MS).

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC022151

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel